BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that five abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, taking place April 25-30, 2025, in Chicago, Illinois. "The data we are presenting at this year's AACR meeting highlights important preclinical analyses of our PRMT5 programs that underscore the potential of these molecules as both standalone treatments and as key combination partners in MTAP-deleted cancers, including in combin

– TNG462 granted Orphan Drug Designation for treatment of pancreatic cancer – – Investigational New Drug (IND) application for TNG456, a next-generation brain-penetrant MTA-cooperative PRMT5 inhibitor, cleared by FDA. Phase 1/2 enrollment expected to begin 1H 2025 – – Clinical collaboration with Eli Lilly to evaluate TNG456 in combination with CDK4/6 inhibitor Verzenio® (abemaciclib) established –  – Data update from ongoing TNG462 monotherapy trial expected in 2025 with focus on pancreatic and lung cancer – – Cash position of $258 million as of December 31, 2024, with cash runway expected to fund operations into 3Q 2026 – BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics,

BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Feb. 20, 2025-- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Tango Therapeutics management is scheduled to participate in three upcoming investment bank conferences. The B Riley Precision Oncology & Radiopharma Conference will be held in New York, NY in late February. The Leerink Global Healthcare Conference and Barclays 27th Annual Global Healthcare Conference will be held in Miami, FL in March. B Riley Precision Oncology & Radiopharma Conference Panel participation on Friday, February 28 at 9:00-10:00

Jefferies initiated coverage of Tango Therapeutics with a rating of Buy and set a new price target of $19.00

Cantor Fitzgerald initiated coverage of Tango Therapeutics with a rating of Overweight

Piper Sandler initiated coverage of Tango Therapeutics with a rating of Overweight and set a new price target of $18.00

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4/A - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

S-8 - Tango Therapeutics, Inc. (0001819133) (Filer)

10-K - Tango Therapeutics, Inc. (0001819133) (Filer)

8-K - Tango Therapeutics, Inc. (0001819133) (Filer)

– Dose escalation ongoing in phase 1/2 trials of lead PRMT5 inhibitors TNG908 and TNG462; additional TNG908 clinical data expected 2024 – – Dose escalation ongoing in phase 1/2 trial of CoREST inhibitor TNG260 and pembrolizumab in patients with STK11 mutant solid tumors – – FDA Fast Track designation granted for TNG348, a novel USP1 inhibitor, for the treatment of BRCA1/2-mutant breast and ovarian cancer; phase 1/2 clinical trial initiation expected 1H 2024 – – Kanishka Pothula, partner at Nextech Ventures, appointed to Board of Directors, replacing Reid Huber, Ph.D., partner at Third Rock Ventures – – Strong cash position of $360 million; cash runway into 2026 expected to fund all clini

Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen

– Dose escalation update from ongoing TNG908 clinical trial confirms proof-of-mechanism for MTA-cooperative tumor-selective PRMT5 inhibition in MTAP-deleted cancers – – FDA clears IND application for TNG260, a first-in-class CoREST complex inhibitor for the treatment of STK11-mutant cancers – – Fast Track designation granted by FDA for TNG260 + anti-PD-1 antibody for the treatment of patients with advanced NSCLC with STK11-loss of function mutations – – Strong cash position of $334 million expected to support advancing precision oncology pipeline into 2026 – BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed

SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)

SC 13D/A - Tango Therapeutics, Inc. (0001819133) (Subject)